DOCSLIB.ORG

Abstracts BOOK

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abstracts BOOK CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE TRANSLATING SCIENCE INTO SURVIVAL SEPTEMBER 25th to 28th, 2019 - PARIS Abstracts BOOK www.cancerimmunotherapyconference.org SESSION A fined as complete response or partial response or stable disease POSTER SESSION A for at least 8 weeks) of 45% (17/38). ORR was 11% (2/19) in PD-L1 negative and 17% (2/12) in PD-L1 positive pts. Pts with 2 lines or more of prior therapy had an ORR of 20% (5/25), regardless of PD-L1 status. Treatment-related Grade 3/4 AEs occurred in 23% Combination therapies with immune of pts, with dehydration, hypotension, and myalgia as the most checkpoint blockers frequently reported (4.7% each), consistent with previous reports. Conclusion : Clinical activity was observed in mTNBC pts treated A001 / Clinical activity of BEMPEG plus NIVO observed in with BEMPEG plus NIVO, notably in pts with poor prognostic fea- tures or negative predictive clinical factors for CPI benefit, includ- metastatic TNBC : preliminary results from the TNBC co- ing negative PD-L1 status. Additional efficacy analyses, including hort of the Ph1/2 PIVOT-02 study ORR, duration of response, and biomarker analyses, will be pre- sented. These data support future development of this doublet in mTNBC pts who are PD-L1 negative at baseline, in combination Sara Tolaney (Dana-Farber Cancer Institute), Capucine Baldini with chemotherapy. This study (NCT02983045) and registration- (Institut Gustave Roussy), Alexander Spira (Virginia Cancer Spe- al studies in other solid tumor settings are ongoing. cialists), Daniel Cho (New York University Langone Medical Cen- ter - NYU Cancer Institute), Giovanni Grignani (Fondazione del Piemonte per l Oncologia IRCCS Candiolo), Dariusz Sawka (POO Keywords : BEMPEG, NKTR-214, Triple-negative breast cancer, Szpital Specjalistyczny w Brzozowie), Fabricio Racca (Instituto Nivolumab. Oncologico Baselga at Hospital Quiron Salud Barcelona), Philippe Bedard (Princess Margaret Cancer Centre), Annemie Rutten (GZA Ziekenhuizen Campus Sint-Augustinus), EJ Liao (Nektar Thera- Immunotherapies, cell based peutics), Sunny Xie (Nektar Therapeutics), Sue Currie (Nektar Therapeutics), Lin Wei (Nektar Therapeutics), Mary Tagliaferri (Nektar Therapeutics), Stina Singel (Nektar Therapeutics), Debu A002 / Skewed T cell distribution in pancreatic cancer Tripathy (MD Anderson Cancer Center). patients Background : Recent advances in the treatment of metastatic tri- ple-negative breast cancer (mTNBC) include the use of check- Cecile Alanio (Institute for Immunology, Department of Systems point inhibitor (CPI) therapy. CPIs, in combination with chemo- Pharmacology and Translational Therapeutics, University of Penn- therapy, has been shown to prolong survival in mTNBC pts with sylvania, Perelman School of Medicine, Philadelphia, USA), Katelyn PD-L1 positive baseline status. However, CPI monotherapy is less T Byrne (Abramson Cancer Center and Department of Medicine, active, with objective response rates (ORR) ranging from 5% (Ad- University of Pennsylvania, Philadelphia, USA), Mohamed Ab- ams, Dirix) to 10% (Emens). ORR with CPI monotherapy also ap- del-Hakeem (Institute for Immunology, Department of Systems pears to be lower in PD-L1 negative baseline pts, ranging from Pharmacology and Translational Therapeutics, University of Penn- 0% (Emens) to 5% (Adams), as well as in 2L pts, with reported ≥ sylvania, Perelman School of Medicine, Philadelphia, USA), Takuya ORR of 6% (Emens). Another reported negative predictive factor Ohtani (Institute for Immunology, Department of Systems Phar- for CPI benefit in these pts includes prior taxane (Schmid). Thus, macology and Translational Therapeutics, University of Pennsyl- more effective CPI treatment combinations are needed, partic- vania, Perelman School of Medicine, Philadelphia, USA), Meredith ularly in pts with PD-L1 negative tumors. The safety and clinical Stone (Abramson Cancer Center and Department of Medicine, activity of bempegaldesleukin (BEMPEG or NKTR-214), a CD-122 University of Pennsylvania, Philadelphia, USA ; Division of Hema- preferential IL-2 pathway agonist, plus the anti-PD1 CPI, nivolum- tology-Oncology, Department of Medicine, Perelman School of ab (NIVO) was evaluated in PIVOT-02, a multicenter Phase 1/2 Medicine, University of Pennsylvania, Philadelphia, Pennsylvania), study in multiple solid tumor settings and includes a cohort of pts Jean-Christophe Beltra (Institute for Immunology, Department of with mTNBC. PIVOT-02 recently reported promising preliminary Systems Pharmacology and Translational Therapeutics, Univer- clinical activity and safety data for pts with metastatic melano- sity of Pennsylvania, Perelman School of Medicine, Philadelphia, ma and urothelial cancers. This is the first report of BEMPEG plus USA), Josephine Giles (Institute for Immunology, Department of NIVO in mTNBC. Systems Pharmacology and Translational Therapeutics, Univer- sity of Pennsylvania, Perelman School of Medicine, Philadelphia, Methods : 43 pts with mTNBC received BEMPEG (0.006 mg/kg) USA), Austin Huffman (Abramson Cancer Center and Depart- + NIVO (360 mg) q3w. Pts were categorized by line of therapy ment of Medicine, University of Pennsylvania, Philadelphia, USA), (1L, 1L but early relapse [defined as metastatic relapse within 12 Bertram Bengsch (Department of Medicine II, Gastroenterology, months of last chemotherapy in EBC setting], 2L, 3L). In addi- ≥ Hepatology, Endocrinology, and Infectious Diseases, University tion to PD-L1 status, other predictive or prognostic clinical factors Medical Center Freiburg and Signalling Research Centres BIOSS were assessed, including the following five : age, disease-free in- and CIBSS, University of Freiburg, Germany), Sarah Henrickson terval, LDH, number and type of metastatic sites, and prior tax- (Institute for Immunology, Department of Systems Pharmacol- ane. Response was assessed every 3 cycles by RECIST v1.1. Per ogy and Translational Therapeutics, University of Pennsylvania, protocol, ORR was evaluated in the 38 pt efficacy-evaluable pop- Perelman School of Medicine, Philadelphia, USA), Nan-Ping Weng ulation, defined as pts with at least 1 post-baseline tumor assess- (Lymphocyte Differentiation Section, Laboratory of Molecular ment (5 were not evaluable : 3 clinical progressions, 2 deaths due Biology and Immunology, NIA, National Institutes of Health, Bal- to progressive disease after 1 cycle). Baseline immunohistochem- timore, Maryland 21224), Janáe A Ritz-Romeo (Division of Hema- istry (IHC) analysis for PD-L1 was performed using 28-8 pharmDx tology-Oncology, Department of Medicine, Perelman School of (Dako) and defined as PD-L1 negative (<1% tumor cell expression) Medicine, University of Pennsylvania, Philadelphia, Pennsylvania), and PD-L1 positive ( 1% tumor cell expression). Safety and toler- ≥ Mark O’Hara (Division of Hematology-Oncology, Department of ability were assessed by adverse event (AE) analysis reported by Medicine, Perelman School of Medicine, University of Pennsyl- CTCAE v4.03. vania, Philadelphia, Pennsylvania), J Joseph Melenhorst (Center of Cellular Immunotherapies, Abramson Cancer Center and the Results : 42 of the 43 patients reported at least 1 of the 5 poor Department of Pathology and Laboratory Medicine, Perelman prognostic or negative predictive clinical factors for CPI ben- School of Medicine, University of Pennsylvania, Philadelphia, PA efit, with a median of 2. Baseline factors that indicated a poor 19104, USA), Simon Lacey (Center of Cellular Immunotherapies, prognosis population include : young age (21% 40 years old), ≤ Abramson Cancer Center and the Department of Pathology and 51% PD-L1-negative, 65% who had received 2 lines or more treat- Laboratory Medicine, Perelman School of Medicine, University of ment in the metastatic setting, and 40% had elevated LDH. Lung Pennsylvania, Philadelphia, PA 19104, USA), Regina M Young (Cen- and liver were the most common sites of metastasis occurring in ter of Cellular Immunotherapies, Abramson Cancer Center and 46.5% and 23.3% respectively, and 44% of all pts had 3 meta- ≥ the Department of Pathology and Laboratory Medicine, Perelman static organ sites. ORR in the 38 efficacy-evaluable pts was 13% School of Medicine, University of Pennsylvania, Philadelphia, PA (5/38), regardless of PD-L1 status, with a disease control rate (de- 19104, USA), Gregory L Beatty (Abramson Cancer Center and FIFTH CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCESEPT. 25 - 28, 2019 - PARIS, FRANCE 2 SESSION A Department of Medicine, University of Pennsylvania, Philadelphia, associated with GBM, are non-ideal targets because they are also USA ; Division of Hematology-Oncology, Department of Medicine, expressed in other normal organs. We show that “prime-and-kill” Perelman School of Medicine, University of Pennsylvania, Phila- dual antigen recognition circuits can overcome this challenge in delphia, Pennsylvania), Robert H Vonderheide (Abramson Cancer vitro and in vivo. Where a synthetic Notch (synNotch) receptor Center and Department of Medicine, University of Pennsylvania, that recognizes a specific but heterogeneous antigen (EGFRvIII) is Philadelphia, USA), Carl H June (Center of Cellular Immunothera- engineered to locally induce expression of a CAR that kills neigh- pies, Abramson Cancer Center and the Department of Pathology boring cells expressing tumor-associated antigens. This type of and Laboratory Medicine, Perelman School of Medicine, Universi- circuit spatially integrates recognition of multiple antigen
Load more

Recommended publications
  • Genetics of Interleukin 1 Receptor-Like 1 in Immune and Inflammatory Diseases
    Current Genomics, 2010, 11, 591-606 591 Genetics of Interleukin 1 Receptor-Like 1 in Immune and Inflammatory Diseases Loubna Akhabir and Andrew Sandford* Department of Medicine, University of British Columbia, UBC James Hogg Research Centre, Providence Heart + Lung Institute, Room 166, St. Paul's Hospital, 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada Abstract: Interleukin 1 receptor-like 1 (IL1RL1) is gaining in recognition due to its involvement in immune/inflamma- tory disorders. Well-designed animal studies have shown its critical role in experimental allergic inflammation and human in vitro studies have consistently demonstrated its up-regulation in several conditions such as asthma and rheumatoid ar- thritis. The ligand for IL1RL1 is IL33 which emerged as playing an important role in initiating eosinophilic inflammation and activating other immune cells resulting in an allergic phenotype. An IL1RL1 single nucleotide polymorphism (SNP) was among the most significant results of a genome-wide scan inves- tigating eosinophil counts; in the same study, this SNP associated with asthma in 10 populations. The IL1RL1 gene resides in a region of high linkage disequilibrium containing interleukin 1 receptor genes as well as in- terleukin 18 receptor and accessory genes. This poses a challenge to researchers interested in deciphering genetic associa- tion signals in the region as all of the genes represent interesting candidates for asthma and allergic disease. The IL1RL1 gene and its resulting soluble and receptor proteins have emerged as key regulators of the inflammatory proc- ess implicated in a large variety of human pathologies We review the function and expression of the IL1RL1 gene.
    [Show full text]
  • Interleukin-18 As a Therapeutic Target in Acute Myocardial Infarction and Heart Failure
    Interleukin-18 as a Therapeutic Target in Acute Myocardial Infarction and Heart Failure Laura C O’Brien,1 Eleonora Mezzaroma,2,3,4 Benjamin W Van Tassell,2,3,4 Carlo Marchetti,2,3 Salvatore Carbone,2,3 Antonio Abbate,1,2,3 and Stefano Toldo2,3 1Department of Physiology and Biophysics, 2Victoria Johnson Research Laboratories, and 3Virginia Commonwealth University Pauley Heart Center, School of Medicine, and 4Pharmacotherapy and Outcome Sciences, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, United States of America Interleukin 18 (IL-18) is a proinflammatory cytokine in the IL-1 family that has been implicated in a number of disease states. In animal models of acute myocardial infarction (AMI), pressure overload, and LPS-induced dysfunction, IL-18 regulates cardiomy- ocyte hypertrophy and induces cardiac contractile dysfunction and extracellular matrix remodeling. In patients, high IL-18 levels correlate with increased risk of developing cardiovascular disease (CVD) and with a worse prognosis in patients with established CVD. Two strategies have been used to counter the effects of IL-18:IL-18 binding protein (IL-18BP), a naturally occurring protein, and a neutralizing IL-18 antibody. Recombinant human IL-18BP (r-hIL-18BP) has been investigated in animal studies and in phase I/II clinical trials for psoriasis and rheumatoid arthritis. A phase II clinical trial using a humanized monoclonal IL-18 antibody for type 2 diabetes is ongoing. Here we review the literature regarding the role of IL-18 in AMI and heart failure and the evidence and challenges of using IL-18BP and blocking IL-18 antibodies as a therapeutic strategy in patients with heart disease.
    [Show full text]
  • Biomarker Quantitation Assay Guide
    Biomarker quantitation assay guide Quantitate protein: ELISA l Antibody pairs l ProQuantum HS immunoassays l ProcartaPlex immunoassays Quantitate mRNA: QuantiGene multiplexed gene expression assays Our Invitrogen™ portfolio offers a variety of assays for quantitation of single proteins and mRNA, as well as mix-and-match and ready-to-use panels for correlated multiplexing using the Luminex® platform. Our extensive portfolio of assays includes: • ELISA and antibody pair kits • ProQuantum™ high-sensitivity immunoassay kits • ProcartaPlex™ multiplex immunoassay kits • QuantiGene™ Plex gene expression assays Additionally, Thermo Fisher Scientific supports your quantitation assay needs with accessory reagents and instruments for a comprehensive offering. Use this guide to help identify your needs, and then contact your sales representative if you have questions or go to thermofisher.com/quantitatebiomarkers Contents Biomarker background 4 Biomarker quantitation assay platforms 7 Single-analyte quantitation ELISA kits 9 Antibody pair kits 11 ProQuantum high-sensitivity immunoassay kits 12 Accessory reagents and equipment 14 Multianalyte quantitation Luminex xMAP technology 17 ProcartaPlex multiplex immunoassay kits 19 ProcartaPlex high-sensitivity immunoassay kits 27 ProcartaPlex Platinum immunoassay kits 28 Custom assay development service 30 Multiplexed gene expression assays 32 QuantiGene Plex assays 32 Additional gene expression solutions 38 Comprehensive immunoassay product listing 40 Biomarker background Highly referenced kits you can
    [Show full text]
  • The Relevance of Clinical, Genetic and Serological Markers
    AUTREV-01901; No of Pages 18 Autoimmunity Reviews xxx (2016) xxx–xxx Contents lists available at ScienceDirect Autoimmunity Reviews journal homepage: www.elsevier.com/locate/autrev Review Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers Raquel López-Mejías a, Santos Castañeda b, Carlos González-Juanatey c,AlfonsoCorralesa, Iván Ferraz-Amaro d, Fernanda Genre a, Sara Remuzgo-Martínez a, Luis Rodriguez-Rodriguez e, Ricardo Blanco a,JavierLlorcaf, Javier Martín g, Miguel A. González-Gay a,h,i,⁎ a Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain b Division of Rheumatology, Hospital Universitario la Princesa, IIS-IPrincesa, Madrid, Spain c Division of Cardiology, Hospital Lucus Augusti, Lugo, Spain d Rheumatology Division, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain e Division of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain f Division of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain g Institute of Parasitology and Biomedicine López-Neyra, IPBLN-CSIC, Granada, Spain h School of Medicine, University of Cantabria, Santander, Spain i Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa article info abstract Article history: Cardiovascular disease (CV) is the most common cause of premature mortality in patients with rheumatoid ar- Received 7 July 2016 thritis (RA). This is the result of an accelerated atherosclerotic process. Adequate CV risk stratification has special Accepted 9 July 2016 relevance in RA to identify patients at risk of CV disease.
    [Show full text]
  • Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure: the HOMAGE Study
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Enlighten Ferreira, J. P. et al. (2019) Proteomic bioprofiles and mechanistic pathways of progression to heart failure: the HOMAGE study. Circulation, 12(5), e005897. (doi:10.1161/CIRCHEARTFAILURE.118.005897) This is the author’s final accepted version. There may be differences between this version and the published version. You are advised to consult the publisher’s version if you wish to cite from it. http://eprints.gla.ac.uk/186516/ Deposited on: 13 May 2019 Enlighten – Research publications by members of the University of Glasgow http://eprints.gla.ac.uk Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure: the HOMAGE (Heart OMics in AGEing) study João Pedro Ferreira, MD, PhD1,2* & Job Verdonschot, MD3,4*; Timothy Collier, PhD5; Ping Wang, PhD4; Anne Pizard, PhD1,6; Christian Bär, MD, PhD7; Jens Björkman, PhD8; Alessandro Boccanelli, MD9; Javed Butler, MD, PhD10; Andrew Clark, MD, PhD11; John G. Cleland, MD, PhD12,13; Christian Delles, MD, PhD14; Javier Diez, MD, PhD15,16,17,18; Nicolas Girerd, MD, PhD1; Arantxa González, MD, PhD15,16,17; Mark Hazebroek, MD, PhD3; Anne-Cécile Huby, PhD1; Wouter Jukema, MD, PhD19; Roberto Latini, MD, PhD20; Joost Leenders, MD, PhD21; Daniel Levy, MD, PhD22,23; Alexandre Mebazaa, MD, PhD24; Harald Mischak, MD, PhD25; Florence Pinet, MD, PhD26; Patrick Rossignol, MD, PhD1; Naveed Sattar, MD, PhD27; Peter Sever, MD, PhD28; Jan A. Staessen, MD, PhD29,30; Thomas Thum, MD, PhD7,31; Nicolas Vodovar, PhD24; Zhen-Yu Zhang, MD29; Stephane Heymans, MD, PhD3,32,33** & Faiez Zannad, MD, PhD1** *co-first authors **co-last authors 1 Université de Lorraine, Inserm, Centre d’Investigations Cliniques- Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
    [Show full text]
  • Interleukin-18 in Health and Disease
    International Journal of Molecular Sciences Review Interleukin-18 in Health and Disease Koubun Yasuda 1 , Kenji Nakanishi 1,* and Hiroko Tsutsui 2 1 Department of Immunology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan; [email protected] 2 Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-798-45-6573 Received: 21 December 2018; Accepted: 29 January 2019; Published: 2 February 2019 Abstract: Interleukin (IL)-18 was originally discovered as a factor that enhanced IFN-γ production from anti-CD3-stimulated Th1 cells, especially in the presence of IL-12. Upon stimulation with Ag plus IL-12, naïve T cells develop into IL-18 receptor (IL-18R) expressing Th1 cells, which increase IFN-γ production in response to IL-18 stimulation. Therefore, IL-12 is a commitment factor that induces the development of Th1 cells. In contrast, IL-18 is a proinflammatory cytokine that facilitates type 1 responses. However, IL-18 without IL-12 but with IL-2, stimulates NK cells, CD4+ NKT cells, and established Th1 cells, to produce IL-3, IL-9, and IL-13. Furthermore, together with IL-3, IL-18 stimulates mast cells and basophils to produce IL-4, IL-13, and chemical mediators such as histamine. Therefore, IL-18 is a cytokine that stimulates various cell types and has pleiotropic functions. IL-18 is a member of the IL-1 family of cytokines. IL-18 demonstrates a unique function by binding to a specific receptor expressed on various types of cells.
    [Show full text]
  • Major Projects
    Major Projects S/N Image Project Description Height: 468m Built Up Area: 686,000sqm 1 Chongqing Rui'an Phase II Steel Tonnage: 67,000MT The tallest building in west China. Height: 350.6m 2 Shenyang Hang Lung Plaza Built Up Area: 480,000sqm Steel Tonnage: 60,000MT Height: 309m 3 Hefei Evergrande Center Built Up Area: 247,600sqm Steel Tonnage: 21,800MT Height: 170m Hangzhou Wanyin International 4 Built Up Area: 92,000sqm Building Steel Tonnage: 12,000MT S/N Image Project Description Height: 597m Built Up Area: 370,000sqm 5 Tianjin Goldin 117 Tower Steel Tonnage: 120,000MT The tallest building in north China. Height: 384m 6 Shenzhen Shun Hing Square Built Up Area: 150,000sqm Steel Tonnage: 25,000MT Height: 492m Built Up Area: 380,000sqm 7 Shanghai World Finance Center Steel Tonnage: 67,000MT The tallestroof height in the world in that time. Height: 342m 8 Zhenjiang Suning Plaza Built Up Area: 390,000sqm Steel Tonnage: 28,000MT S/N Image Project Description Height: 400m Shenzhen China Resources 9 Built Up Area: 260,000sqm Building Steel Tonnage: 33,000MT Height: 208m Shanghai Taiping Financial 10 Built Up Area: 110,000sqm Tower Steel Tonnage: 11,000MT Height: 432m Guangzhou International 11 Built Up Area: 450,000sqm Financial Center Steel Tonnage: 40,000MT Height: 660m (5 basement + 118 tower) Built Up Area: 450,000sqm Steel Tonnage: 100,000MT Height: 660m (5 basement + 118 12 Guangzhou Taikoo Hui Plaza tower) Built Up Area: 450,000sqm Steel Tonnage: 100,000MT Height: 212m Built Up Area: 460,000sqm Steel Tonnage: 19,000MT S/N Image Project Description Height: 234m Built Up Area: 550,000sqm Beijing CCTV New Office 13 Steel Tonnage: 140,000MT Building The biggest steel structure building in the world in terms of steel tonnage.
    [Show full text]
  • Research Report 2016 Medical University of Innsbruck
    Research Report 2016 Research Report 2016 Medical University of Innsbruck Cover, middle picture: Platelets and fungal hyphae, inverted image; © Hermann/Speth Contents Foreword � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � 5 Medical Theoretical Research Units Biocenter Medical Biochemistry � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � 8 Neurobiochemistry � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � 12 Clinical Biochemistry � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � 14 Biological Chemistry � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � 16 Cell Biology � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � 18 Genomics and RNomics � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � �
    [Show full text]
  • Semi-Annual Report 2019
    CSG HOLDING CO., LTD. SEMI-ANNUAL REPORT 2019 Chairman of the Board: CHEN LIN August 2019 CSG Semi-annual Report 2019 Section I Important Notice, Content and Paraphrase Board of Directors and the Supervisory Committee of CSG Holding Co., Ltd. (hereinafter referred to as the Company) and its directors, supervisors and senior executives hereby confirm that there are no any fictitious statements, misleading statements, or important omissions carried in this report, and shall take all responsibilities, individual and/or joint, for the facticity, accuracy and completeness of the whole contents. Ms. Chen Lin, Chairman of the Board, Mr. Wang Jian, responsible person in charge of accounting and Ms.Wang Wenxin, principal of the financial department (accounting officer) confirm that the Financial Report enclosed in the semi-annual report of the Company is true, accurate and complete. All directors were present at the meeting of the Board for deliberating the semi-annual report of the Company in person. This report involves future plans and some other forward-looking statements, which shall not be considered as virtual promises to investors. Investors are kindly reminded to pay attention to possible risks. Details of the risk factors and countermeasures of future development have been well-described in this report, please find in Section IV Performance Discussion and Analysis. The Company has no plans of cash dividend distribution, bonus shares being sent or converting capital reserve into share capital. This report is prepared both in Chinese and English. Should there be any inconsistency between the Chinese and English versions, the Chinese version shall prevail. 1 CSG Semi-annual Report 2019 Content Section I Important Notice, Content and Paraphrase .......................................................................
    [Show full text]
  • Seibersdorf, 26
    HEALTH & ENVIRONMENT Seminar Series 2011 Preclinical and translational imaging in oncology, neurology and immunology Bernd Pichler, University of Tübingen, Germany AIT Austrian Institute of Technology May 4, 2011, 15:30-16:30 Tech Gate, Conference Room 0.3 (Ground Floor) Donau-City Str. 1, 1220 Vienna Abstract Preclinical imaging, and specifically molecular imaging methods such as positron emission tomography (PET) or single photon emission computed tomography (SPECT) as well as magnetic resonance imaging (MRI), experience enormous attention in the realm of basic biomedical and translational research. Modern imaging technologies hold a great potential to expand our current knowledge in many life science areas. Especially the prospect to obtain more detailed information in the field of oncology, neurology, immunology and infectious diseases in combination with the research of new and highly specific targets and biomarkers significantly enhances preclinical and translational research. The lecture will provide an overview of the strengths of different imaging technologies and will focus on scientific preclinical applications in oncology, neurology and immunology. It will also reveal our approaches and activities in biomarker and radiotracer development. Further, it will review the current state-of-the-art of combined PET/MRI for multiparametric imaging in basic science and clinical diagnostic. Biosketch Prof. Bernd Pichler is Chair of the Department of Preclinical Imaging and Radiopharmacy, Clinic of Radiology, University of Tübingen, Germany. Dr. Pichler studied electrical engineering with a focus on biomedical engineering and cybernetics at the Technical University of Munich. He finished his diploma thesis in 1997 at the Max-Planck-Institute for Physics, Munich and the Department of Nuclear Medicine, Technical University of Munich, in the field of detector development for small animal positron emission tomography.
    [Show full text]
  • Prof. Dr. Bernd Pichler
    Prof. Dr. Bernd Pichler Personal Data Status/Function: Director of Department Scientific focus: Bernd Pichler works in the field of PET and PET/MR imaging science since more than 15 years and pioneered (together with Siemens) the development of preclinical and clinical PET/MRI. He performed research at the TU Munich, the MPI for Physics in Munich, UC Davis USA and the University of Tuebingen. Bernd Pichlers's lab is focussing on interdisciplinary basic research in biomedicine with the use of state-of-the-art imaging technologies. This includes multi-modality imaging in oncology, immunology and neurology as well as the development of new imaging technologies and innovative imaging probes. In recent years, he has published widely on the preclinical as well as clinical implementation of PET/MR imaging. Phone: +49 7071 29-83443 Fax: +49 07071 29-4451 Email: [email protected] Education and qualifications 2007: Postdoctoral thesis (Habilitation) in Preclinical Imaging, Title “Molekulare Bildgebung in der Präklinischen Forschung”, Eberhard Karls University Tübingen, Mentor: Prof. Dr. C. Claussen 2001: Doctoral thesis in Physics, Technische Universität München, Mentor: Prof. Dr. M. Schwaiger/Prof. Dr. Ziegler 1992 – 1997: College of Electrical Engineering, Biomedical Engineering, at the Technische Universität München, Diploma of Electrical Engineering, Biomedical Engineering Work Experience since 2020 Dean of the Faculty of Medicine of the Eberhard Karls University of Tübingen 2011 - 2014 Deputy Managing Research Director of
    [Show full text]
  • Annual 2015 Report the Most Sought-After Top-Notch Cultural Tourism Destination
    Evergrande Real Estate Group Limited 恒大地產集團有限公司 (incorporated in the Cayman Islands with limited liability) Stock Code: 3333 Annual 2015 Report The most sought-after top-notch cultural tourism destination ENTERTAINMENT BUSINESS EXHIBITION CONFERENCE CULTURE TRAVEL GUANGDONG PROVINCE HUBEI PROVINCE JIANGSU PROVINCE ANHUI PROVINCE JIANGXI PROVINCE JILIN PROVINCE 1 The Second Jinbi Garden Guangzhou 67 Evergrande Palace Wuhan 134 Evergrande Splendor Nanjing 189 Evergrande City Hefei 262 Evergrande City Nanchang 321 Evergrande Oasis Changchun 2 The Third Jinbi Garden Guangzhou 68 Evergrande Oasis Wuhan 135 Evergrande Palace Nanjing 190 Evergrande Royal View Garden Hefei 263 Evergrande Oasis Nanchang 322 Evergrande City Changchun 3 Evergrande Royal Palace Guangzhou 69 Evergrande City Wuhan 136 Evergrande Emerald Court Nanjing 191 Evergrande International Center Hefei 264 Evergrande Metropolis Nanchang 323 Evergrande International Center Changchun 4 Evergrande Scenic Garden Zengcheng Guangzhou 70 Evergrande Metropolis Wuhan 137 Evergrande Venice on the Sea Qidong 192 Evergrande Plaza Hefei 265 Evergrande Royal View Garden Nanchang 324 Evergrande Royal Scenic Changchun 5 Evergrande Jewelry Guangzhou 71 Evergrande Royal Scenic Bay Wuhan 138 Evergrande Metropolis Danyang 193 Evergrande Oasis Tongling 266 Evergrande Metropolis Jingdezhen 325 Evergrande Metropolis Changchun 6 Evergrande Royal Scenic Peninsula Foshan 72 Evergrande Splendor Ezhou 139 Evergrande City Danyang 194 Evergrande Palace Wuhu 267 Evergrande Atrium Xinyu 326 Evergrande City
    [Show full text]